FineHeart obtains Czech health authority approval to commence First in Human clinical study
Severe Heart Failure patients to be treated with the FLOWMAKER®, FineHeart’s fully implantable breakthrough innovation to restore cardiac output.
Bordeaux, France, October 3, 2023 - FineHeart S.A, a medical device company developing innovative devices for cardiology announced today that it has received authorization from the SUKL (the Czech Republic State Institute for the Control of Medicinal Products) to carry out “A prospective, single arm, single center, First in Human Study to evaluate the safety and performance at 30 days of the FineHeart FLOWMAKER® in subjects with advanced heart failure.”